# Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma

> **NCT00379262** · PHASE3 · COMPLETED · sponsor: **Hong Kong Nasopharyngeal Cancer Study Group Limited** · enrollment: 803 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Adjuvant chemotherapy using PF (5-Fluorouracil )
- **DRUG:** Induction chemotherapy using PF (5-Fluorouracil)

## Key facts

- **NCT ID:** NCT00379262
- **Lead sponsor:** Hong Kong Nasopharyngeal Cancer Study Group Limited
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2017-05
- **Final completion:** 2018-12
- **Target enrollment:** 803 (ACTUAL)
- **Last updated:** 2019-08-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00379262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00379262, "Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00379262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*